2015/04/08

In new Nature paper, Raze Therapeutics co-founder David Sabatini discovers role for 1C metabolism in glioblastoma

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance.

Press Release

back to overview